REMAP-CAP TRIAL INVESTIGATORS SAY WILL CONTINUE TO STUDY EFFECTS OF CONVALESCENT PLASMA ON MODERATELY ILL HOSPITALISED COVID-19 PATIENTS
Remap-Cap Trial Investigators Say Will Continue To Study Effects Of Convalescent Plasma On Moderately Ill Hospitalised Covid-19 Patients
![Reuters logo](/images/reuters.jpg)